Spyre Therapeutics (SYRE) Enterprise Value (2016 - 2025)
Spyre Therapeutics' Enterprise Value history spans 11 years, with the latest figure at -$756.5 million for Q4 2025.
- For Q4 2025, Enterprise Value fell 25.44% year-over-year to -$756.5 million; the TTM value through Dec 2025 reached -$756.5 million, down 25.44%, while the annual FY2025 figure was -$756.5 million, 25.44% down from the prior year.
- Enterprise Value reached -$756.5 million in Q4 2025 per SYRE's latest filing, down from -$484.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$38.5 million in Q1 2023 to a low of -$756.5 million in Q4 2025.
- Average Enterprise Value over 5 years is -$291.0 million, with a median of -$219.5 million recorded in 2023.
- Peak YoY movement for Enterprise Value: skyrocketed 47.32% in 2022, then tumbled 1159.53% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$93.1 million in 2021, then surged by 40.18% to -$55.7 million in 2022, then plummeted by 508.99% to -$339.3 million in 2023, then crashed by 77.76% to -$603.1 million in 2024, then decreased by 25.44% to -$756.5 million in 2025.
- Per Business Quant, the three most recent readings for SYRE's Enterprise Value are -$756.5 million (Q4 2025), -$484.5 million (Q3 2025), and -$526.6 million (Q2 2025).